Yuhao Jing

Mr. Yuhao Jing

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
XLXin Liu
Xin Liu
YDYun Ding
Yun Ding
JRJie Ren
Jie Ren
JLJiuzhen Li
Jiuzhen Li
KWKai Wang
Kai Wang
DSDaqiang Sun
Daqiang Sun
Objectives: This study aimed to determine the factors affecting the diagnostic efficacy of frozen sections for assessing tumor spread through air spaces (STAS) and to provide suggestions for the sampling of these frozen sections. Methods: Cases of invasive adenocarcinoma with a pathological diagnosis of stage IA-IIIB were screened, and frozen and paraffin sections were reviewed. Using paraffin sections as the gold standard, the consistency of frozen pathological diagnosis of STAS was calculated. Factors that may affect STAS diagnosis in frozen sections were screened, and a nomogram was drawn. Results: The sensitivity of frozen sections in STAS diagnosis was 55.4% (108/195), the specificity was 74.5% (254/321), and the kappa value was 0.35. In the subsequent logistic regression, the ratio of the tissue diameters of the frozen and paraffin sections, number of frozen section sheets, clarity of the tumor boundary, and number of alveoli from the peritumoral area to tissue edge were all statistically significantly significant (p < 0.05) factors affecting the frozen STAS diagnostic efficacy. Conclusions: The diagnostic efficacy of frozen sections for STAS is poor. In our study, the tissue diameter ratio of the frozen to paraffin sections, the number of frozen sections, the clarity of the tumor boundary, and the number of alveoli from the peritumoral tissue to the tissue edge were considered independent factors affecting diagnostic consistency. The accuracy of the frozen section analysis in STAS diagnosis can be improved by our reasonable suggestions on frozen sampling, making it a reliable indicator of the surgical method.

1 July 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
YJYuhao Jing
Yuhao Jing
YZYifan Zhao
Yifan Zhao
ZZZhenbao Zhou
Zhenbao Zhou
XLXin Li
Xin Li
WDWolfram C. M. Dempke
Wolfram C. M. Dempke
DSDaqiang Sun
Daqiang Sun
Background: Small cell lung cancer (SCLC) is a highly aggressive thoracic malignancy for which immune checkpoint inhibitors (ICIs) combined with chemotherapy have become standard first-line therapy according to recent randomized clinical trials. However, real-world data on the efficacy of atezolizumab-based regimens remain limited, especially in patients with high tumor burden or brain metastases. The aim of this study was to evaluate the real-world effectiveness of atezolizumab plus etoposide and platinum (EP) chemotherapy compared to EP alone as first-line treatment in patients with extensive-stage SCLC (ES-SCLC). Methods: This retrospective cohort study included patients diagnosed with ES-SCLC at Tianjin Chest Hospital between January 2019 and December 2024. Eligible patients received either atezolizumab plus EP or EP chemotherapy alone as first-line treatment, with at least four completed cycles. Inverse probability of treatment weighting (IPTW) was used to balance the baseline covariates. The primary outcomes were overall survival (OS) and progression-free survival (PFS), which were analyzed with Kaplan-Meier curves and Cox proportional hazards models with robust variance estimation. Results: A total of 95 patients were included (42 in the atezolizumab group and 53 in the EP-only group). After IPTW adjustment, the combination group demonstrated improved OS as compared to the EP-only group [median 9.7 vs. 7.1 months; hazard ratio (HR) =0.51, 95% confidence interval (CI): 0.30–0.94]; meanwhile, the PFS showed similar median values between the groups (5.8 vs. 5.7 months), but the immunotherapy group (atezolizumab plus etoposide and platinum) exhibited a delayed separation in survival curves and a favorable HR (0.42, 95% CI: 0.21–0.86), suggesting durable benefit. Subgroup analysis revealed significant OS and PFS benefits among patients without brain metastases, while results in the brain metastasis subgroup were inconclusive due to the limited sample size. Conclusions: In this real-world cohort of patients with ES-SCLC, atezolizumab combined with EP chemotherapy was associated with improved survival outcomes as compared to EP alone, even in a clinically heterogeneous population. These findings support the broader applicability of immune-chemotherapy in routine practice and underscore the potential benefit for patients without brain metastases.

1 April 2026 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
YJYuhao Jing
Yuhao Jing
YZYifan Zhao
Yifan Zhao
ZZZhenbao Zhou
Zhenbao Zhou
JWJianyu Wang
Jianyu Wang
YWYanbo Wang
Yanbo Wang
XLXin Li
Xin Li
Background: In the immunotherapy era, most patients with extensive-stage small-cell lung cancer (ES-SCLC) still experience early progression, whereas only a minority derive more durable benefit. Most existing prognostic models were developed primarily with chemotherapy-treated cohorts and have not been adequately validated in patients receiving first-line chemoimmunotherapy. We aimed to develop and internally validate a robust nomogram integrating metastatic topography and inflammatory biomarkers to improve baseline risk stratification in contemporary ES-SCLC. Methods: We analyzed a multicenter retrospective cohort of 605 treatment-eligible ES-SCLC patients treated in routine clinical practice with first-line platinum-etoposide (EP) with or without programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. Patients were randomly split into a training cohort (n=421) and a validation cohort (n=184). A multivariable Cox proportional hazards model incorporating systemic immune-inflammation index (SII), lung immune prognostic index (LIPI), tumor marker status, metastatic sites, and treatment modality was used to develop a nine-variable nomogram and an integer-based scoring system. Model performance was evaluated by concordance index (C-index), time-dependent area under the curve (tAUC), calibration, and decision curve analysis (DCA), with head-to-head comparisons against three published prognostic models. Results: Independent prognostic factors indicating worse prognosis included high neuron-specific enolase (NSE), elevated SII, unfavorable LIPI, malignant pleural effusion (MPE), and specific metastatic sites (liver, bone, brain, and adrenal). Chemoimmunotherapy was independently associated with longer overall survival (OS) after adjustment for baseline prognostic factors. The nomogram showed consistent discrimination with C-indices of approximately 0.75 in both cohorts, and tAUCs generally exceeding 0.70 across 12–24 months. Calibration indicated close agreement between predicted and observed survival probabilities, and DCA demonstrated meaningful net clinical benefit over default strategies. Compared with the Dang, Gao, and Ge models, our nomogram achieved higher tAUCs with better stability across training and validation cohorts. Conclusions: This nine-variable nomogram provides a clinically accessible tool for baseline risk stratification in treatment-eligible patients with ES-SCLC receiving contemporary EP-based therapy in routine practice. It may support individualized prognostic assessment, determination of follow-up intensity, and supportive-care planning. However, its applicability to patients with poorer performance status or heavier disease burden requires further external validation.

20 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FCFeng Chen
Feng Chen
XCXia Chen
Xia Chen
WZWenkang Zong
Wenkang Zong
YJYuhao Jing
Yuhao Jing
WXWenchao Xia
Wenchao Xia
YXYijun Xu
Yijun Xu
Background: Women with small-cell lung cancer (SCLC) often have longer overall survival (OS) without a corresponding progression-free survival (PFS) advantage. We investigated when this difference emerges.Methods: We conducted a two-cohort secondary analysis. SEER 17 data (2004–2023) assessed associations of sex with all-cause, SCLC-specific, and other-cause mortality. A hospital cohort was analyzed using an illness–death model of documented progression, death without previously documented progression, and death after progression. Multivariable Cox models, Aalen–Johansen state probabilities, restricted mean time in states, and sensitivity analyses were applied.Results: SEER included 107,474 patients and 99,299 deaths. Female sex was associated with lower all-cause mortality (hazard ratio [HR], 0.85; 95% CI, 0.84–0.86), SCLC-specific mortality (HR, 0.86; 95% CI, 0.85–0.87), and other-cause mortality (HR, 0.79; 95% CI, 0.76–0.82). The hospital cohort included 605 patients. Median OS was 17.5 months in women and 10.2 months in men, whereas median PFS was 7.9 and 7.6 months. Adjusted female-to-male HRs were 0.73 (95% CI, 0.55–0.95) for OS and 0.94 (95% CI, 0.75–1.17) for PFS. Female sex was not associated with progression (HR, 1.00; 95% CI, 0.75–1.33) or death without previously documented progression (HR, 0.91; 95% CI, 0.65–1.28), but was associated with lower mortality after progression (HR, 0.43; 95% CI, 0.27–0.68). Through 24 months, women accumulated 1.49 additional months alive after progression without additional progression-free time. The post-progression association persisted in sensitivity analyses and was not modified by recorded immune-checkpoint inhibitor exposure.Conclusions: The female OS advantage in SCLC appears to arise predominantly after documented progression. Prospective studies should examine post-progression treatment, supportive care, host resilience, and relapse biology.

10 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YJYuhao Jing
Yuhao Jing
ZZZhenbao Zhou
Zhenbao Zhou
MLMiao Li
Miao Li
GSGuangzhi Sun
Guangzhi Sun
XWXin Wang
Xin Wang
XLXin Li
Xin Li
Background: Randomized trials support sublobar resection for selected small peripheral lung cancers, but real-world outcomes may vary by procedure type, nodal assessment, and pathological risk. Methods: We performed a two-stage real-world analysis. Stage 1 included 22,864 patients with lung adenocarcinoma ≤3 cm from a node-assessed N0M0 SEER cohort. Stage 2 included 872 patients with node-negative lung adenocarcinoma from a multi-institutional, single-center-dominant clinicopathological cohort. The primary endpoint was disease-free survival (DFS). Results: In SEER, sublobar resection was associated with higher all-cause mortality (HR 1.31, 95% CI 1.23–1.38) and lung cancer-specific death (HR 1.38, 95% CI 1.27–1.51). Procedure-specific estimates were smaller for segmentectomy than for wedge resection and were attenuated after adjustment for examined lymph-node count. In the clinicopathological cohort, the primary postoperative model showed a higher DFS hazard with sublobar resection (HR 1.75, 95% CI 1.08–2.83), with a similar estimate after overlap weighting (HR 1.75, 95% CI 1.08–2.85). However, the association was not statistically clear after propensity-score matching (HR 1.41, 95% CI 0.76–2.63), 60-month restriction (HR 1.09, 95% CI 0.58–2.03), or restriction to a comparable-follow-up cohort (HR 1.57, 95% CI 0.88–2.78). The proportional-hazards assumption for DFS was violated, and late estimates were based on sparse risk sets and were unstable. The recurrence association was predominantly locoregional, and increasing Core-HRPF burden was associated with progressively worse prognosis. Conclusions: Real-world sublobar resection is a heterogeneous exposure. Observed outcome associations varied by procedure type, nodal assessment, analytical specification, and follow-up horizon and should not be interpreted as evidence that sublobar resection is intrinsically inferior to lobectomy.